Peptide guide

Tesamorelin: What the Evidence Actually Shows

Also called TH9507, Egrifta, Egrifta SV, Egrifta WR, GHRH analogue

Tesamorelin is one of the few peptides in the anti-aging and body-composition conversation that is genuinely FDA-approved, and that fact is doing more work in marketing than it can honestly bear. It was approved in November 2010 for one thing: reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Its pivotal trials cut visceral fat by about 15% over 26 weeks while leaving subcutaneous fat and total body weight essentially unchanged — and the label states, in its own Limitations of Use, that it is not indicated for weight loss management because its effect is weight neutral. It also raised IGF-1 by about 81%, and when treatment stopped, the visceral fat came back. Here is what the trials measured, in whom, and what the approval does and does not cover.

By Grant Delaney, Research EditorAugust 2026

FDA approval

2010one indication

Largest trial

412randomized

Longest reported duration

52weeks

Phase 3 records, both in HIV

2of 24 registered studies

Compound

What it is

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone — the hypothalamic signal that tells the pituitary to release growth hormone — given as a daily subcutaneous injection. It works one step upstream of injected growth hormone: rather than supplying the hormone, it stimulates the body's own basal and pulsatile secretion without altering pulse frequency. It was developed and tested in adults on antiretroviral therapy who had accumulated visceral adipose tissue, a population in which reduced growth hormone secretion and increased visceral fat both appear to contribute to dyslipidaemia and cardiovascular risk.^1,8

Mechanism

How it works

The intended chain is short: more endogenous growth hormone, more IGF-1, and preferential lipolysis in the visceral fat depot. All three links have been measured. In the 412-participant pivotal trial, IGF-1 rose 81.0% on tesamorelin against a 5.0% fall on placebo, while visceral adipose tissue fell 15.2% against a 5.0% increase. A pooled analysis of the two phase 3 trials found the effect concentrated in exactly the depot the mechanism predicts: visceral adipose tissue fell by a treatment effect of 15.4% while abdominal subcutaneous adipose tissue did not change significantly, a treatment effect of 0.6%. A 2026 meta-analysis of five randomized trials put the same pattern in absolute terms — visceral adipose tissue down 27.71 cm², trunk fat down 1.18 kg, lean body mass up 1.42 kg, and no significant change in subcutaneous adipose tissue or body-mass index.^1,2,6

Evidence

What the trials found

Randomized trials

Evidence strength: Randomized trials. Randomized controlled trials in humans, at scale.

The pivotal evidence is two multicentre, double-blind, placebo-controlled phase 3 trials in adults on antiretroviral therapy with excess abdominal fat. The larger randomized 412 patients, 86% of them men, to 2 mg of tesamorelin or placebo daily for 26 weeks; visceral adipose tissue fell 15.2% against a 5.0% increase on placebo, triglycerides fell 50 mg/dL against a 9 mg/dL rise, and the total-to-HDL cholesterol ratio fell 0.31 against a 0.21 rise. Pooled across both trials, 806 patients were randomized 2:1 and then re-randomized at week 26 for a 26-week extension; those who stayed on tesamorelin for the full 52 weeks held a 17.5% visceral fat reduction, and the extension phase reported that on discontinuation the visceral fat reaccumulated. Later, smaller, investigator-initiated trials extended the question to the liver: a 50-participant randomized trial at one hospital found reductions in both visceral fat and liver fat over six months, and a 61-participant trial in people with HIV and fatty liver disease found a 37% relative reduction in hepatic fat fraction at 12 months, with 35% of the tesamorelin group reaching a fraction below 5% against 4% on placebo. Two 2026 reviews assessed the evidence outside that indication: an orthopaedic narrative review of injectable peptides concluded that tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence, and a sports medicine review groups it with peptides marketed direct to patients for which rigorous human safety data are scarce.^{1,2,3,4,5,7,9}

15.2%

Visceral fat reduction — 26 wk

412-participant pivotal trial, against a 5.0% increase on placebo.

81%

IGF-1 increase — 26 wk

Same trial; IGF-1 fell 5.0% on placebo.

0.6%

Subcutaneous fat treatment effect

Pooled phase 3 analysis: the change in subcutaneous fat was not statistically significant.

—

Effect on body weight

The label states it is not indicated for weight loss management, as it has a weight neutral effect; a 2026 meta-analysis found no significant change in body-mass index.

Where the fat moved: visceral vs subcutaneous (%)

Visceral fat, 26 wk (pivotal)

15.2 %

Visceral fat, 26 wk (pooled effect)

15.4 %

Visceral fat, 52 wk

17.5 %

Subcutaneous fat, 26 wk (pooled effect)

0.6 %

Body-mass index change

No data

Trial size, participants randomized

Liver fat RCT (MGH)

NAFLD in HIV RCT

Phase 3 extension

263

Pivotal phase 3

412

Both phase 3 trials pooled

806

How to read the evidence meter

Four steps, weakest to strongest. Most peptides sold for a goal light up one. We show the step the published human evidence actually reaches — not the step the seller implies.

AnecdotalUser reports and forum consensus. No controlled data.
Animal onlyRodent or cell studies. Nothing published in humans.
Early humanSmall, open-label, or phase 1/2 trials. Promising, unproven.
Randomized trialsRandomized controlled trials in humans, at scale.

Timeline

Development pipeline

Complete
Preclinical
Complete
Phase 1
Complete
Phase 2
Complete
Phase 3
Two trials in HIV-associated lipodystrophy, 806 patients pooled, plus a 26-week extension
5 — Current step
FDA review & approval
BLA 022505 approved November 2010; one indication as of August 2026

Summary

What the evidence does — and doesn't — support

Approved, for one thing

A ClinicalTrials.gov search for tesamorelin returned 24 studies in August 2026, and both phase 3 records in that set — NCT00123253 (412 participants) and its extension NCT00608023 (263) — enrolled adults with HIV-associated lipodystrophy. As of August 2026 the EGRIFTA WR label lists a single indication and states in its Limitations of Use that the drug is not indicated for weight loss management.

What the evidence supports

A roughly 15% reduction in visceral adipose tissue over 26 weeks in adults with HIV-associated lipodystrophy
Improved triglycerides and total-to-HDL cholesterol ratio in the pivotal trial
Reduced liver fat in two later randomized trials in people with HIV
An increase in lean body mass of 1.42 kg in a 2026 meta-analysis of five randomized trials
An effect sustained across 52 weeks of continuous treatment

What it does not support

Weight loss — the label states it is not indicated for it and describes the effect as weight neutral
Reduction of subcutaneous fat — the pooled phase 3 change was not statistically significant
Tendon, ligament, or muscle repair — no registered tesamorelin trial lists such a condition
A lasting effect after stopping — visceral fat reaccumulated on discontinuation
Use outside HIV-associated lipodystrophy as an approved indication

Reality check

The catch

The approval is real and it is narrow. As of August 2026 the DailyMed label for EGRIFTA WR reads: indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Its Limitations of Use then say three things that rarely make it into the marketing — that long-term cardiovascular safety has not been established, that it is not indicated for weight loss management as it has a weight-neutral effect, and that there are no data supporting improved adherence to antiretroviral therapy. Weight neutral is the phrase to sit with: the trials moved fat from one compartment, not off the body. A 2026 meta-analysis of five randomized trials found no significant change in body-mass index or in subcutaneous adipose tissue. The benefit also does not persist: the 52-week extension reported that on discontinuation, visceral fat reaccumulated. And the population is specific. A ClinicalTrials.gov search for tesamorelin returned 24 studies in August 2026; both phase 3 records in that set — NCT00123253, 412 participants, and its extension NCT00608023, 263 — enrolled adults with HIV-associated lipodystrophy. The rest of the set lists conditions including fatty liver disease, mild cognitive impairment, COPD, peripheral nerve injury, type 2 diabetes, and abdominal obesity with growth hormone deficiency; none of the 24 lists a tendon, ligament, or muscle injury as a condition studied. A 2026 narrative review in a sports medicine journal put it plainly: tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence.

Dosing

Dosing evidence

The trial dose and the current label dose are not the same number, and the two marketed formulations do not share a dose either. Every pivotal and investigator-initiated trial cited on this page used 2 mg subcutaneously once daily: 26 weeks in the phase 3 trials, 52 weeks with the extension, six months in the 50-participant liver trial, and 12 months in the 61-participant fatty liver trial. As of August 2026 the EGRIFTA WR label — the 11.6 mg-per-vial formulation — specifies 1.28 mg subcutaneously once daily into the abdomen, and states explicitly that EGRIFTA WR and EGRIFTA SV, the 2 mg-per-vial formulation, differ in dosage, reconstitution and storage and are not substitutable. Anyone reading a trial dose as a label dose, or one formulation's dose as the other's, is reading two different products as one. This page reports what trials assigned and what labels specify; it does not tell any reader what to take.^1,2,3,4,5

Already have a dose in mind? Our reconstitution calculator converts it to syringe units. It does not suggest one.

Safety

Safety and side effects

In the 412-participant trial, adverse events did not differ significantly between groups, though more patients on tesamorelin withdrew because of an adverse event, and no significant differences were observed in glycemic measures. The 52-week extension found the prevalence of adverse events and serious adverse events comparable to the initial phase, with changes in glucose parameters over 52 weeks that were not clinically significant. The 50-participant liver trial did detect a transient glucose signal: fasting glucose rose 9 mg/dL on tesamorelin against 2 mg/dL on placebo at two weeks, a difference that was no longer significant at six months. The 2026 meta-analysis of five randomized trials reported arthralgia, myalgia, paraesthesia and injection-site reactions such as erythema, with no significant change in CD4+ T-cell counts. Against that, the label's own warnings are broader than the trials' adverse-event tables: as of August 2026 EGRIFTA WR carries warnings for increased risk of neoplasms, elevated IGF-1, fluid retention, glucose intolerance and diabetes, hypersensitivity, injection-site reactions, and increased mortality in patients with acute critical illness, and it is contraindicated in disruption of the hypothalamic-pituitary axis, active malignancy, and pregnancy.^1,3,4,6

Approved for this use and available by prescription.

What was approved, and when

An openFDA drugsFDA search returns tesamorelin acetate under BLA 022505, sponsored by Theratechnologies, with an original approval dated November 10, 2010 as a Type 1 new molecular entity, followed by a series of labeling and manufacturing supplements through March 2025. Two marketed formulations sit under that history, EGRIFTA SV and EGRIFTA WR. The DailyMed label for EGRIFTA WR, as of August 2026, gives one indication: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. That single sentence is the entire approved scope, sixteen years after approval.

The gap this page exists to hold open

Tesamorelin is discussed in two different worlds. In one, it is a specialist drug for a specific complication of long-term antiretroviral therapy, with two phase 3 trials, a pooled analysis, a meta-analysis, and a label. In the other, it is a growth-hormone-axis peptide for body recomposition and aging, discussed alongside compounds with no human trials at all. The evidence from the first world does not transfer to the second, and the label says why in one line: not indicated for weight loss management, as it has a weight neutral effect.

The 2026 meta-analysis makes the same point quantitatively. Across five randomized trials it found visceral adipose tissue down 27.71 cm², trunk fat down 1.18 kg, hepatic fat down 4.28 percentage points and lean body mass up 1.42 kg — and no significant reduction in subcutaneous adipose tissue or body-mass index ⁶. That is a redistribution result. Someone whose goal is a smaller number on a scale is looking at a drug whose own approved label tells them it does not do that.

Where the non-HIV research actually went

The registry set is not exclusively HIV. Among the 24 ClinicalTrials.gov records for tesamorelin in August 2026 are a completed phase 2 trial in abdominal obesity with growth hormone deficiency, completed phase 2 trials in mild cognitive impairment and aging, a terminated phase 2 in COPD, a recruiting phase 2 in peripheral nerve injury, and a completed phase 2 in type 2 diabetes. A 2015 review of the human GHRH literature covers both the HIV-infected populations and individuals with general obesity, reporting reduced visceral fat, improved lipids and reduced markers of cardiovascular risk, and closing by saying that further research is needed on long-term efficacy and safety of this treatment modality ⁸. That review is from 2015; the two phase 3 records in the registry set remain the HIV-lipodystrophy trials.

What stopping does

The extension phase answered this directly and the answer is unambiguous: effects on visceral adipose tissue were sustained across 52 weeks of continuous treatment, and upon discontinuation of tesamorelin, visceral adipose tissue reaccumulated ³. Its authors state the implication in the conclusion — the effects do not last beyond the duration of treatment. That places tesamorelin in the same category as the incretin drugs on our tirzepatide page: a maintenance therapy whose benefit is contingent on continuing it, not a course of treatment that resets something.

Why a peptide site is careful here

Peptides marketed for tissue repair and body composition often borrow credibility from tesamorelin — the approved one in the category. Two 2026 reviews put it in that context explicitly. A sports medicine narrative review lists tesamorelin among approved and unapproved peptides marketed direct to patients and notes that rigorous human safety data are scarce across much of that group ⁷. An orthopaedic review states directly that tesamorelin, approved for HIV-associated lipodystrophy, has no supporting orthopaedic evidence ⁹. Our BPC-157 page covers the other end of that same spectrum: a compound with rodent data and no completed human trial at all.

Questions

Frequently asked questions

Is tesamorelin FDA-approved?

Yes, and for one indication. An openFDA drugsFDA search returns tesamorelin acetate under BLA 022505, sponsored by Theratechnologies, originally approved November 10, 2010. As of August 2026 the EGRIFTA WR label gives its indication as the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Nothing beyond that indication is FDA-approved.

Does tesamorelin cause weight loss?

The label answers this in its own Limitations of Use: it is not indicated for weight loss management, as it has a weight neutral effect. The trials moved fat between compartments rather than off the body — a 2026 meta-analysis of five randomized trials found visceral adipose tissue down 27.71 cm² and trunk fat down 1.18 kg, with no significant change in body-mass index or subcutaneous adipose tissue.

How much visceral fat did tesamorelin remove in trials?

In the 412-participant pivotal trial, visceral adipose tissue fell 15.2% over 26 weeks while it rose 5.0% on placebo. Pooled across both phase 3 trials, the 26-week treatment effect was 15.4%, and participants who continued for the full 52 weeks held a 17.5% reduction. Those figures are for adults on antiretroviral therapy with HIV-associated abdominal fat accumulation, which is the population that was studied.

What happens when you stop tesamorelin?

The 26-week extension phase measured it: effects on visceral adipose tissue were sustained through 52 weeks of continuous treatment, and on discontinuation the visceral fat reaccumulated. Its authors concluded that the effects do not last beyond the duration of treatment.

What dose of tesamorelin was used?

Every trial cited on this page used 2 mg subcutaneously once daily. The current label dose is different: as of August 2026 EGRIFTA WR, the 11.6 mg-per-vial formulation, specifies 1.28 mg subcutaneously once daily, and the label states that EGRIFTA WR and EGRIFTA SV differ in dosage, reconstitution and storage and are not substitutable. A trial dose is not a label dose and one formulation's dose is not the other's — and neither is a recommendation from this page.

Does tesamorelin help tendon, muscle or joint healing?

A ClinicalTrials.gov search for tesamorelin returned 24 studies in August 2026, and none of them lists a tendon, ligament, or muscle injury as a condition studied. A 2026 orthopaedic narrative review that specifically evaluated injectable peptides for musculoskeletal use stated that tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence.

What are tesamorelin's risks?

In the trials, adverse events were broadly comparable to placebo, with more withdrawals for adverse events on tesamorelin, a transient rise in fasting glucose at two weeks in one 50-participant trial that had resolved by six months, and arthralgia, myalgia, paraesthesia and injection-site reactions in a 2026 meta-analysis. The label is broader: as of August 2026 EGRIFTA WR carries warnings for increased risk of neoplasms, elevated IGF-1, fluid retention, glucose intolerance and diabetes, hypersensitivity, injection-site reactions and increased mortality in acute critical illness, and contraindications including disruption of the hypothalamic-pituitary axis, active malignancy and pregnancy. The label is the authoritative list; this is a summary of it.

Glossary

Key terms

GHRH analogue: A drug that mimics growth hormone-releasing hormone, prompting the pituitary to secrete the body's own growth hormone rather than supplying growth hormone directly.
Visceral adipose tissue: Fat stored around the internal organs, measured here by CT scan. It is a different compartment from the subcutaneous fat under the skin.
Lipodystrophy: An abnormal distribution of body fat. In this context, the fat accumulation that can develop in people on long-term antiretroviral therapy.
Limitations of Use: A labeled section stating what an approved drug is not for. Tesamorelin's says it is not indicated for weight loss management.
IGF-1: Insulin-like growth factor 1, the downstream marker of growth hormone activity. It rose 81.0% in the pivotal trial and is also a labeled warning.
Not substitutable: Label language meaning two formulations of the same drug cannot be swapped one for one — EGRIFTA WR and EGRIFTA SV differ in dosage, reconstitution and storage.

Sources

References

Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/18057338/
Falutz J, Mamputu JC, Potvin D, et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/20554713/
Falutz J, Allas S, Mamputu JC, et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. https://pubmed.ncbi.nlm.nih.gov/18690162/
Stanley TL, Feldpausch MN, Oh J, et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. https://pubmed.ncbi.nlm.nih.gov/25038357/
Stanley TL, Fourman LT, Feldpausch MN, et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The Lancet HIV. https://pubmed.ncbi.nlm.nih.gov/31611038/
Badran AS, Helal A, Shata KS, et al. (2026). Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity Research & Clinical Practice. https://pubmed.ncbi.nlm.nih.gov/41545261/
Mendias CL, Awan TM (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/41966639/
Stanley TL, Grinspoon SK (2015). Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Hormone & IGF Research. https://pubmed.ncbi.nlm.nih.gov/25555516/
Mayfield CK, Bolia IK, Feingold CL, et al. (2026). Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/41476424/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.